Published in final edited form as:

Transplantation. 1999 January 27; 67(2): 266–272.

LONG-TERM RESULTS OF PANCREAS TRANSPLANTATION UNDER TACROLIMUS IMMUNOSUPPRESSION¹

Mark L. Jordan^{3,2}, Ron Shapiro⁴, H. Albin Gritsch^{3,5}, Francesca Egidi^{3,6}, Ajai Khanna⁴, Carlos A. Vivas³, Velma P. Scantlebury⁴, John J. Fung⁴, Thomas E. Starzl⁴, and Robert J. Corry⁴

³Division of Urologic Surgery and Transplantation, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

⁴Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Abstract

Background—The long-term safety and efficacy of tacrolimus in pancreas transplantation has not yet been demonstrated. The observation of prolonged pancreatic graft function under tacrolimus would indicate that any potential islet toxicity is short-lived and clinically insignificant. We report herein the results of pancreas transplantation in patients receiving primary tacrolimus immunosuppression for a minimum of 2 years.

Methods—From July 4, 1994 until April 18, 1996, 60 patients received either simultaneous pancreas-kidney transplant (n=55), pancreas transplant only (n=4), or pancreas after kidney transplantation (n=1). Baseline immunosuppression consisted of tacrolimus and steroids without antilymphocyte induction. Azathioprine was used as a third agent in 51 patients and mycophenolate mofetil in 9. Rejection episodes within the first 6 months occurred in 48 (80%) patients and were treated with high-dose corticosteroids. Antilymphocyte antibody was required in eight (13%) patients with steroid-resistant rejection.

Results—With a mean follow-up of 35.1 ± 5.9 months (range: 24.3–45.7 months), 6-month and 1-, 2-, and 3-year graft survival is 88%, 82%, 80%, and 800/" (pancreas) and 98%, 96%, 93%, and 91% (kidney), respectively. Six-month and 1-, 2-, and 3-year patient survival is 100%, 98%, 98%, and 96.5%. Mean fasting glucose is 91.6 ± 13.8 mg/dl. and mean glycosylated hemoglobin is $5.1 \pm 0.7\%$ (normal range: 4.3–6.1%). Mean tacrolimus dose is 6.5 ± 2.6 mg/day and mean prednisone dose 2.0 ± 2.9 mg/day at follow-up. Complete steroid withdrawal was possible in 31 (65%) of the 48 patients with functioning pancreases.

Conclusions—These data show for the first time that tacrolimus is a safe and effective long-term primary agent in pancreas transplantation and provides excellent long-term islet function without evidence of toxicity while permitting steroid withdrawal in the majority of patients.

Simultaneous pancreas-kidney (SPK^{*}) transplantation has enjoyed increasing success over the last decade and has therefore become accepted therapy for diabetic patients with end-stage renal disease. However, with both SPK, and even more so with pancreas transplantation alone

¹Presented at the 24th Annual Meeting of the American Society of Transplant Surgeons, May 13–15, 1998, Chicago, IL.

Copyright © 1999 by Lippincott Williams & Wilkins

²Address correspondence to: Mark L. Jordan, M. D., F.A.C.S., Division of Urologic Surgery, Suite 700, 3471 Fifth Avenue, Pittsburgh, PA 15213.

³Current affiliation: Department of Urology, University of California at Los Angeles.

⁶Current affiliation: Department of Medicine, University of Tennessee Medical Center.

(PTA) and pancreas after kidney transplantation (PAK), success is limited by rejection rates with cyclosporine (CsA)-based therapy reported as high as 60–80%, even when induction antilymphocyte therapy has been used (1–3). The introduction of tacrolimus (TAC) has ushered in a new era for immunosuppression of solid organ recipients. Its use is associated with a lower incidence of acute rejection in primary kidney transplantation compared with CsA in both U.S. and European multicenter trials (4,5). TAC also has the ability to rescue kidney, liver, and pancreas grafts from rejection refractory to standard immunosuppressive protocols (6–8) and has the added advantage of permitting concomitant steroid tapering in both adult (9) and pediatric (10) renal transplantation, with up to 60% of patients eventually weaned from prednisone. Additional data suggest that TAC may also yield longer half-lives for kidney transplants than standard CsA-based regimens (11). These observations have encouraged several centers, (8,12,13) including our own (14), to evaluate the safety and efficacy of TAC as primary therapy for pancreas transplantation. Thus far, reports with relatively short-term (one year or less) follow-up have confirmed the utility of TAC, and in some cases, suggested it is superior to CsA for SPK (8,12,14). Because of the reported potential for diabetogenicity associated with TAC (4–6,9,15), there has been reluctance by some centers to adopt this drug for primary pancreas transplantation, even though the reputed diabetogenicity has been shown to be short-lived and reversible in the majority of cases (4–6,9,10,15). Nevertheless, we felt it important to examine in more detail the outcome of pancreas transplantation under TAC, especially in the long term, paying particular attention to the long-term diabetogenic potential, which has utmost relevance in the pancreas transplant recipient. We, therefore, report herein our experience in the first 60 pancreas recipients transplanted at our institution under TAC immunosuppression, all of whom have been followed for a minimum of 2 years. The results support the use of TAC as a safe long-term agent for pancreas transplantation without an increased risk of posttransplant diabetes compared with traditional CsA-based regimens.

PATIENTS AND METHODS

Donor and recipient demographics

Between July 4, 1994 and April 18, 1996, 60 patients (29 men, 31 women) with a mean age of 36.8 ± 6.3 years (range: 25.8–52.6 years) received TAC-based immunosuppression as primary therapy for cadaver pancreas transplantation. Fifty-five (92%) patients underwent simultaneous pancreas-kidney (SPK) transplantation, 4 (6.5%) a pancreas transplant alone (PTA), and 1 (1.5%) a pancreas after a previous kidney transplant (PAK). Of the 55 SPK patients, 49 (89%) were primary kidney transplant recipients and 6 (11%) were undergoing repeat transplantation (5 second, 1 third). All patients were undergoing primary pancreas transplantation. The mean number of HLA matches and mismatches was 1.4 ± 1.1 and 4.3 ± 1.2 , respectively (Table 1). The mean donor age was 26.2 ± 12.9 years (range: 6–54 years). Eight donors were ≥ 45 years old, and 14 were ≤ 15 years old. The mean cold ischemia time (CIT) for the kidney transplants was 14.9 ± 5.2 hr (range: 6–25 hr) and for the pancreas transplants 16.8 ± 4.9 hr (range: 7–28 hr). Seventeen of the pancreas transplants were drained into the bladder, and 43 were drained enterically.

Immunosuppression

All patients received primary TAC-based immunosuppression with a steroid tapering regimen, as described previously (14). Antilymphocyte antibody induction was not used. In addition to TAC and steroids, 51 (85%) patients received azathioprine (AZA) at 2 mg/kg/day and 9 (15%) received mycophenolate mofetil (MMF) (CellCept^R) at 1 g twice daily. AZA and MMF doses

* Abbreviations: AZA, azathioprine; CIT, cold ischemia time; CMV, cytomegalovirus; CsA, cyclosporine A; HbA_{1C}, glycosylated hemoglobin; MMF, mycophenolate mofetil; PAK, pancreas after kidney; PTA, pancreas transplant alone; PTDM, posttransplant diabetes mellitus; SCr, serum creatinine; SPK, simultaneous pancreas-kidney; TAC, tacrolimus.

were titrated to maintain a white blood cell count $>5000/\text{mm}^3$ and according to gastrointestinal side effects in the case of MMF. Patients received intravenous TAC at 0.05 mg/kg/day for 5 days post-operatively, followed by an initial oral dose of 0.15 mg/kg twice daily. The TAC dose was adjusted to achieve target whole blood trough levels of 20–25 ng/ml in the first 2 weeks after transplant, 15–20 ng/ml by 1 month, 10–15 ng/ml by 2 months, 7–12 ng/ml by 6 months, and 5–10 ng/ml thereafter. In the presence of stable graft function steroids were tapered by 2.5–5 mg every 2 weeks with the aim of complete steroid weaning by 12–18 months. All patients received prophylaxis for *Pneumocystis carinii* pneumonia with trimethoprim-sulfamethoxazole. Cytomegalovirus (CMV)-seronegative recipients of CMV-seropositive organ donors (n=14) had biweekly testing for CMV antigen (pp65) and were treated with a 14-day course of intravenous ganciclovir if CMV antigenemia was positive. Routine prophylaxis for CMV was not given.

Rejection

The diagnosis of acute rejection was suspected in patients with a $> 10\%$ increase in baseline serum creatinine (SCr) or a rising or sustained increase in serum lipase (15), or both. The presence of rejection was confirmed either by fine needle aspiration biopsy of the kidney or pancreas or core needle biopsy of the kidney, or both. Biopsy-confirmed rejection was treated with either intravenous solumedrol boluses (generally 500 mg daily for 3 days) or by a tapering steroid recycle (200 mg to 20 mg over 6 days). Steroid-resistant rejection episodes were treated with antilymphocyte antibody (OKT3 or ATGAM) for 7–14 days.

Statistical analysis

Patient survival rate was calculated from the date of transplantation until death, and the graft (kidney or pancreas) survival rate from the date of transplantation until graft failure or patient death. Survival curves were generated using the Kaplan-Meier (product limit) method. Data were analyzed for statistical significance by analysis of variance where appropriate.

RESULTS

Patient and graft survival

The mean follow-up was 35.1 ± 5.9 months (range: 24.3–45.7 months). Overall 6-month and 1-, 2-, and 3-year actuarial patient survival was 100%, 98%, 98%, and 96.5% (Fig. 1). Of 60 recipients, 57 (95%) are currently alive. One PTA patient died of a brain stem infarct 10 months after transplant; this patient had lost her graft at 3 months to recurrent rejection. The two other deaths occurred in SPK patients. One patient died of multiple system organ failure and inanition 25 months after transplant with a functioning kidney graft; this patient had lost the pancreas to severe pancreatitis 13 days after transplant. A second SPK patient died 39 months after transplant of unknown causes on dialysis; the lymphocytotoxic cross-match had become positive on the third day after transplant and she subsequently lost her kidney and pancreas at 12 and 21 days after transplant, respectively, owing to antibody-mediated rejection.

Overall 6-month and 1-, 2-, and 3-year actuarial pancreas graft survival was 88%, 82%, 80% and 80%, and kidney graft survival 98%, 96%, 93%, and 91% (Fig. 2). Of the 60 pancreas grafts, 48 (80%) are currently functioning. The 12 pancreas graft losses occurred in 12 (20%) patients—10 of the 55 SPK patients and 2 of the 4 PTA patients.

Cumulative pancreas graft loss from rejection was 3% at 6 months, 6.5% at 1 year, and 8% at 2 and 3 years. Of 56 kidney grafts, 49 (88%) are currently functioning. Cumulative kidney graft loss from rejection was 3.5% at 6 months, 3.5% at 1 year, 7% at 2 years, and 9% at 3 years. The causes of pancreas and kidney graft loss are shown in Table 2. Overall, 12 pancreases were lost; 9 within 22 days after transplantation and 1 each at 2.5 months, 8.8 months, and 20

months after transplant. Four pancreases were lost to rejection, three to thrombosis, two to infection (one *Candida*, one splenic artery anastomotic pseudoaneurysm with abscess), two as a result of severe pancreatitis, and one to duodenal ischemia with fistula. High-risk donor factors contributing to the eight non-immunologic graft losses could be identified in five cases and included prolonged CIT (23 hr) and pressor support in one, a ligated inferior pancreaticoduodenal artery that was unrecognized at the time of organ recovery in one, donor obesity (weight 127 kg) in one, donor hypernatremia (Na = 170 mEq/L) in one, and donor pneumococcal sepsis with a hemorrhagic capillary leak syndrome in one. Renal graft losses were caused by rejection in six cases and patient death in one case.

Rejection

Biopsy-proven rejection episodes within the first 6 months after transplantation occurred in 48 of 60 (80%) patients, including 43 of 55 SPK (78%), 4 of 4 PTA (100%), and the 1 PAK patient. Rejection episodes were classified as mild (Banff grade I) in 33 (69%) patients, moderate (Banff grade II) in 13 (27%), and severe (Banff grade III) in 2 (4%). Acute rejection was treated with high-dose corticosteroids and optimization of TAC levels initially in all cases, with reversal in 40 of 48 (83%). Of the 48 patients with rejection, 8 (17%) did not respond to high-dose steroids and were treated with a 7–14-day course of antilymphocyte antibody (OKT3 in 6, ATGAM in 2) with reversal of rejection in 7 (88%). In 2 of the 60 patients, the rejection episodes were irreversible and progressed to kidney graft loss at 12 and 32 days and pancreas graft loss at 21 and 14 days after transplant, respectively. One of these patients had developed a positive lymphocytotoxic cross-match after transplant, as described above.

Long-term immunosuppression and outcome

All patients received TAC for primary immunosuppression. Two patients (one SPK, on PTA) were converted to Neoral at 6 and 19 months after transplant, respectively, in unsuccessful attempts to reverse ongoing rejection; both patients lost their pancreas grafts, at 8.8 months and 20 months after transplant, respectively, to chronic rejection. The SPK patient continues to have a functioning renal transplant (SCr = 1.8 mg/dl) at 34 months after transplant. An additional patient who had two rejection episodes was switched to Neoral 12 months after transplant for persistent hyperglycemia (glucose > 180 mg/dl) but continues to have elevated glucose levels.

Of the nine patients originally on TAC-MMF, two (one PTA, one SPK) have lost their grafts (pancreas and kidney, respectively) to rejection. Four of the nine TAC-MMF patients were taken off MMF; three were switched to AZA because of gastrointestinal side effects resistant to MMF dose reduction, and one PTA patient was switched to Cytoxan and Neoral in an unsuccessful attempt to reverse ongoing rejection. Of the 51 patients originally receiving TAC-azathioprine (TAC-AZA), eight were converted to TAC-MMF because of rejection; of these, one SPK patient lost her kidney transplant to chronic rejection at 35.7 months but continues to have pancreas graft function, and one lost his pancreas to rejection at 20 months but continues to have renal graft function. Overall, of the 51 patients originally on TAC-AZA, pancreas graft loss occurred in 11 patients and kidney graft loss in 6. Of the 48 patients with functioning pancreases, 31 (65%) have been weaned off prednisone at a mean of 17.0 ± 9.9 months (range: 8–39 months) after transplant; 2 are taking 10 mg/day; 3 are taking 7.5 mg/day, 10 are on 5 mg/day, 1 is taking 5 mg and 2.5 mg on alternate days, and 1 is on 2.5 mg/day. One SPK patient had initially been weaned off prednisone 11 months after transplantation but experienced a late mild rejection episode at 14 months, treated successfully with high-dose steroids. This patient currently has good renal and pancreatic graft function (SCr = 1.8 mg/dl, fasting glucose = 81 mg/dl) and is on 10 mg of prednisone daily, in addition to 8 mg of TAC and 500 mg of MMF daily. No other patients weaned off steroids has subsequently had a rejection episode or has been restarted on steroids. Of the 49 patients with functioning kidneys (48 SPK, 1 PAK), the

mean prednisone dose is 2.2 ± 3.2 mg/day; 32 (65%) are currently off prednisone and 3 are taking 10 mg/day, 3 7.5 mg/day, 10 5 mg/day, and 1 is taking 5 and 2.5 mg on alternate days.

Graft function and TAC

Of the 48 patients with a functioning pancreas (45 SPK, 2 PTA, 1 PAK), 47 remain on TAC and 1 has been switched to Neoral because of persistent hyperglycemia (fasting glucose > 180 mg/dl); this latter patient currently has a fasting glucose ranging from 130 to 170 mg/dl on Neoral at 150 mg twice daily, 5 mg of prednisone, and at MMF 500 mg twice daily. In the other 47 patients, the mean TAC dose is 6.3 ± 1.8 mg/day and the mean TAC level is 8.0 ± 2.2 ng/ml. Corresponding mean fasting glucose levels in these 47 patients are 91.6 ± 13.8 mg/dl, and mean glycosylated hemoglobin (HbA_{1C}) is $5.1 \pm 0.7\%$ (normal range: 4.3–6.1%). Fasting glucose, SCr, TAC dose, and TAC levels at corresponding time points after transplantation in the 45 SPK patients with functioning grafts are shown in Table 3. In the two patients with functioning grafts after PTA, mean fasting glucose is 99.5 ± 21.9 mg/dl with a mean TAC level of 11.5 ng/ml (TAC dose of 6.0 ± 2.8 mg/day) at a mean of 31.1 months' follow-up; in the PAK patient, fasting glucose is 69 mg/dl and SCr is 1.2 mg/dl with a trough TAC level of 6.5 ng/ml on a TAC dose on 5 mg of TAC/day at 30 months' follow-up.

Transient hyperglycemic episodes

Transient hyperglycemic episodes (defined as a rise in blood glucose over 180 mg/dl) occurred in a total of 26 patients at a mean of 45.2 ± 118 days after transplant (median: 23 days). These episodes were associated with treatment of rejection in 16 (62%) of 26 cases and TAC toxicity in 1 (4%). Nine patients in whom the cause of hyperglycemia was unknown were evaluated to search for possible donor-related causes that could account for delayed graft function. The mean donor age for these patients was 29 ± 14.8 years (median: 35 years). The mean CIT was 17.5 ± 4.9 hr (median: 18 hr). Seven of nine (78%) of these donors were on pressors before organ retrieval (four were on >2 pressors). In the other two cases, no obvious cause for the transient hyperglycemic episode could be discovered. During transient hyperglycemic episodes, mean blood glucose level was 218 ± 82 mg/dl (median: 200 mg/dl). The mean TAC level during episodes of hyperglycemia was 19.2 ± 9.1 ng/ml (median: 17.6 ng/ml) with a concomitant mean oral TAC dose of 18.5 ± 6.7 mg/day (median: 18 mg/day). In the 16 cases where hyperglycemia was associated with treatment of rejection, intravenous TAC was used to optimize trough TAC levels in 3 patients at a mean dose of 1.5 ± 0.76 mg/day. Bolus therapy with solumedrol was given in all 16 patients to treat rejection. Mean SCr during hyperglycemic episodes was 2.0 ± 1.2 mg/dl. In none of these patients did the transient hyperglycemic episode result in graft loss or diminished long-term pancreatic function, and all have normal glucose metabolism beyond 2 years.

DISCUSSION

Tacrolimus has gained widespread acceptance as an effective immunosuppressive agent in solid organ transplantation as both a primary (4,5,7–10) and rescue agent (6,7,8,17). In randomized trials of TAC and CsA for renal transplantation, short-term outcomes have shown that TAC is superior to CsA in reducing rejection incidence (4,5), and possible long-term advantages for renal allograft half-life have also been described (11). An additional advantage of this drug, demonstrated in our own institution, is its steroid-sparing effects, with complete steroid withdrawal possible in up to 60% of renal allograft recipients (9,10). Accompanying these favorable observations have been concerns over the diabetogenicity of TAC, which has been reported in the short term with an incidence ranging from 6% to 28% of renal transplant patients (4,5,9,10,16). However, the final incidence of posttransplant diabetes mellitus (PTDM) in these studies ranges from 1.4% to 12.6%, which is no different than that in CsA-based regimens, and is reversible in 37–83% (4,5,9,10,16). In our experience, this reversibility

can be maximized with judicious early (over 2–3 months) TAC dose reduction, along with steroid tapering.

Potential reasons for impaired glucose metabolism and transient hyperglycemia in the early postoperative period after pancreas transplantation include impaired early insulin secretion by the recovering ischemic graft, reduced β -cell responsiveness, impaired nonoxidative glucose metabolism, and impaired early inhibition of glucagon secretion (8). The diabetogenic effects of TAC in rats have been shown to involve transcriptional inhibition of insulin mRNA caused by the binding of TAC to FKBP-12, which is present in high concentration in pancreatic B cells, with subsequent inhibition of calcineurin activity in these cells (19). However, when TAC administration (which was given at a higher than therapeutic dose of 10 mg/kg/day in this study) was stopped, insulin mRNA transcription and insulin production normalized (19). Other experimental studies have confirmed that TAC's effects on in vitro inhibition of insulin gene transcription are reversible and are time- and dose-dependent (20). In fact, one study even showed that TAC protects mouse pancreatic islets from streptozocin-induced injury (21). Furthermore, in a randomized trial comparing CsA and TAC in liver transplant recipients, Steinmuller and colleagues (22) found no differences in the incidence of impaired glucose tolerance or clinically significant PTDM. Strumph reported that the oral glucose tolerance test and Hgb_{A1C} levels were unchanged in seven nondiabetic autoimmune subjects after 10 weeks of FK 506 therapy (23). These experimental and clinical observations recapitulate observations made by ourselves (9,10) and others (4,5) demonstrating the reversibility of TAC-induced PTDM.

Despite these observations, justifiable concern has been expressed over the use of a potentially (albeit reversible) diabetogenic agent such as TAC for pancreas transplantation. The short-term safety and efficacy of TAC in pancreas transplantation has been reported in both single-center and multicenter trials for both primary and rescue therapy (8,12–14). Gruessner has recently shown in a follow-up multicenter analysis of TAC immunosuppression for pancreas allograft recipients statistically significant improvements in 1-year graft survival of SPK patients when compared to a matched pair group receiving CsA (12). In his study, only 4% of recipients were converted from TAC to CsA for diabetogenicity by 1 year. However, no details on TAC dosing and levels or steroid dose were provided for these patients (12). Of note, 86% of the recipients in the retrospective multicenter analysis by Gruessner had received anti-T-cell induction therapy along with TAC, steroids, and either azathioprine (94%) or MMF (5%), and steroid tapering was not mentioned. Other studies (13,24–26) have also reported the use of TAC for pancreas transplantation in small numbers of patients with short-term follow-up, but its safety and efficacy in the long term, particularly with respect to the potential for sustained graft function without clinical evidence of islet toxicity, has not been reported. Therefore, we thought it prudent to analyze our experience with TAC for primary pancreas transplantation in patients with a minimum of 2 years' follow-up.

In the current study, 60 patients receiving pancreas transplants between July 4, 1994 and April 18, 1996 have been followed for a mean of 35.1 months. The majority (85%) received TAC-AZA with prednisone. During the latter part of this early experience with TAC-based immunosuppression, MMF was used instead of AZA as a third drug in nine patients. Although our rejection incidence of 80% is somewhat higher than that reported in other recent studies with TAC-based therapy for pancreas transplantation (12), the majority (69%) of these rejections were classified as mild and none of these patients had received anti-T-cell induction therapy. Furthermore, only eight patients (17%) required OKT3 for steroid-resistant rejection. Steroid withdrawal was accomplished in 65% of the patients at a mean of 17.0 ± 9.9 months after transplantation. Prednisone was reinstituted after its discontinuation in only one patient who experienced a late mild rejection episode 1 year after transplantation. The number of patients receiving MMF was too small to draw any meaningful conclusions regarding its

potential benefits as a third agent with TAC-prednisone, although in a larger patient group with shorter follow-up at our institution, MMF appears to confer an immunologic benefit with a lower incidence of rejection (27). MMF has been subsequently incorporated as part of our routine immunosuppressive regimen for pancreas transplantation.

The efficacy of TAC-based immunosuppression without the use of induction antilymphocyte antibody, in both kidney (9,10), and now pancreas transplantation (14), is perhaps best reflected by the current series, in which long-term graft function without evidence of islet toxicity, reflected by mean fasting glucose levels of 90.4 ± 17.6 mg/dl (range: 43–135) and Hgb_{A1C} of $5.1 \pm 0.7\%$ (range: 3.2–6.5%), was observed at a mean follow-up of 35.1 ± 5.9 months. In the group of patients exhibiting transient hyperglycemia, the mean TAC level of 19.2 ± 9.1 and the mean oral TAC dose of 18.5 ± 6.7 mg/day were quite high. Dose reduction resulted in resolution of hyperglycemia in all cases, confirming that the hyperglycemia in these patients was TAC dose-dependent. Furthermore, the glucose remained normal beyond 2 years.

Our center has now performed 147 pancreas transplants under TAC-based immunosuppression. In the initial group of 60 patients reported herein, long-term pancreatic graft function without evidence of islet toxicity along with the ability to taper steroids in 65% of patients, accompanied by a very low incidence (13%) of steroid-resistant rejection requiring antilymphocyte antibody treatment, have reassured us that TAC is both safe and effective for long-term outcome in cadaver pancreas transplantation.

Acknowledgments

The authors are grateful to Dolores McFarland for expert secretarial assistance and to Sheila Fedorek, Loraine Oczypok, Holly Woods, Deborah Good, Igor Dvorchik, and John McMichael for generous assistance with data retrieval and analysis.

REFERENCES

1. Sollinger HW, Knechtle SJ, Reed A, et al. Experience with 100 consecutive simultaneous kidney-pancreas transplants with bladder drainage. *Ann Surg* 1991;214:703. [PubMed: 1741650]
2. Gruessner RWG, Dunn DL, Tzardis PJ, et al. Simultaneous pancreas and kidney transplants versus single kidney transplants and previous kidney transplants in uremic patients and single pancreas transplants in nonuremic diabetic patients: comparison of rejection, morbidity, and long-term outcome. *Transplant Proc* 1990;22:622. [PubMed: 2327003]
3. Sutherland, DER.; Gruessner, RWG. Pancreas transplantation in the United States as reported to the United Network for Organ Sharing (UNOS) and analyzed by the International Pancreas Transplant Registry. In: Terasaki, PI.; Cecka, JM., editors. *Clinical Transplants 1996*. Los Angeles: UCLA Tissue Typing Laboratory; 1997.
4. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A Comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression after cadaveric renal transplantation: FK 506 Kidney Transplant Study Group. *Transplantation* 1997;63:977. [PubMed: 9112351]
5. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK 506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. *Transplantation* 1997;64:436. [PubMed: 9275110]
6. Jordan ML, Naraghi R, Shapiro R, et al. Tacrolimus rescue therapy for renal allograft rejection: five-year experience. *Transplantation* 1997;63:223. [PubMed: 9020321]
7. Fung JT, Starzl TE. FK 506 in solid organ transplantation. *Ther Drug Monit* 1995;17:592. [PubMed: 8588226]
8. Gruessner RWG, Burke GW, Stratta R, et al. A multicenter analysis of the first experience with FK 506 for induction and rescue therapy after pancreas transplantation. *Transplantation* 1996;61:261. [PubMed: 8600635]

9. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of FK 506-based immunosuppression after renal transplantation. *Transplantation* 1995;59:485. [PubMed: 7533343]
10. Shapiro R, Scantlebury VP, Jordan ML, et al. Tacrolimus in pediatric renal transplantation. *Transplantation* 1996;62:1752. [PubMed: 8990356]
11. Gjertson DW, Cecka JM, Terasaki PI. The relative effects of FK 506 and cyclosporine on short and long-term kidney graft survival. *Transplantation* 1995;60:1384. [PubMed: 8545861]
12. Gruessner RWG. for the Tacrolimus Pancreas Transplant Study Group. Tacrolimus in pancreas transplantation: a multicenter analysis. *Clin Transplant* 1997;11:299. [PubMed: 9267719]
13. Stratta RJ. for the FK/MMF Multi-Center Study Group. Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multicenter report. *Transplant Proc* 1997;29:654. [PubMed: 9123463]
14. Corry RJ, Egidi MF, Shapiro R, et al. Tacrolimus without antilymphocyte induction therapy prevents pancreas loss from rejection in 123 consecutive patients. *Transplant Proc* 1998;30:521. [PubMed: 9532157]
15. Sugitani A, Egidi MF, Gritsch HA, Corry RJ. Serum lipase as a marker for pancreatic allograft rejection. *Transplant Proc* 1998;30:645. [PubMed: 9532214]
16. Shapiro R, Scantlebury VP, Jordan ML, et al. Reversibility of tacrolimus induced post-transplant diabetes: an illustrative case and review of the literature. *Transplant Proc* 1997;29:2737. [PubMed: 9290809]
17. Jordan ML, Shapiro R, Vivas CA, et al. FK 506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. *Transplantation* 1994;57:860. [PubMed: 7512293]
18. Christiansen E, Tibell A, Volund AA, et al. Metabolism of oral glucose in pancreas transplant recipients with normal and impaired glucose tolerance. *J Clin Endocrinol Metab* 1997;82:2299. [PubMed: 9215311]
19. Tamura K, Fujimura T, Tsutsami T, et al. Transcriptional inhibition of insulin by FK 506 and possible involvement of FK 506 binding protein-12 in pancreatic beta-cell. *Transplantation* 1995;59:1606. [PubMed: 7539960]
20. Redmon JB, Olson LK, Armstrong MB, Greene MJ, Robertson RP. Effects of tacrolimus (FK 506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. *J Clin Invest* 1996;98:2786. [PubMed: 8981925]
21. Papaccio G, Latronico M, Chieffi Baccari G. The immunosuppressant FK 506 inhibits the damage to mouse pancreatic islets induced by low dose streptozocin. *Cell Tissue Res* 1994;277:573. [PubMed: 7525068]
22. Steinmuller TM, Graf KJ, Schleicher J, et al. The effect of FK 506 versus cyclosporine on glucose and lipid metabolism: a randomized trial. *Transplantation* 1994;58:669. [PubMed: 7524203]
23. Strumph P, Kirsch D, Gooding W, Carroll P. The effect of FK 506 on glycemic response as assessed by the hyperglycemic clamp technique. *Transplantation* 1995;60:147. [PubMed: 7542815]
24. Stegall MD, Simon M, Wachs ME, Chan L, Nolan C, Kam I. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. *Transplantation* 1997;64:1995.
25. Hariharan S, Munda R, Cavallo T, et al. Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. *Transplantation* 1996;61:1161. [PubMed: 8610411]
26. Bartlett ST, Schweitzer EJ, Johnson LB, et al. Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation: a prospective trial of tacrolimus immunosuppression with percutaneous biopsy. *Ann Surg* 1996;224:440. [PubMed: 8857849]
27. Gritsch HA, Egidi MF, Sugitani A, et al. Comparison of azathioprine and mycophenolate mofetil in pancreas transplantation. *Acta Diabetol* 1997;30:162.

FIGURE 1.
Kaplan Meier patient survival of 60 patients receiving SPK (n=55), PAK (n=4), or PTA (n=1).
Numbers in parentheses indicate patients at risk at each time point.

FIGURE 2.

Kaplan Meier kidney (—, n=56) and pancreas (- - -, n=60) graft survival. Numbers in parentheses indicate grafts at risk at each time point.

TABLE 1

HLA matches and mismatches

No. of HLA matches	No. of patients (%)	No. of HLA mismatches	No. of patients (%)
0	15 (25%)	0	0 (0%)
1	22 (37%)	1	2 (3%)
2	12 (20%)	2	4 (7%)
3	9 (15%)	3	8 (13%)
4	2 (3%)	4	16 (27%)
5	0 (0%)	5	23 (38%)
6	0 (0%)	6	7 (12%)

TABLE 2

Causes of graft loss

Graft type	Patient	Date of transplant	Cause of graft loss (time after transplant)	
			Pancreas	Kidney
SPK	RC	9/19/94	Antibody-mediated rejection (21 days)	Antibody-mediated rejection (12 days)
SPK	DB	9/28/94	Thrombosis (1 day)	Normal function (44 months)
SPK	TS	11/7/94	Ischemia of duodenum with fistula ^a (5 days)	Chronic rejection (38.5 months)
SPK	AB	11/26/94	<i>Candida</i> infection (14 days)	Acute rejection (32 days) ^b
SPK	TM	12/7/94	Low-flow necrosis (10 days)	Normal function (40.5 months)
SPK	JM	1/18/95	Thrombosis (1 day)	Normal function (39 months)
SPK	DP	1/21/95	Normal islet function (39 months)	Chronic rejection (35.7 months)
SPK	JG	5/27/95	Recurrent rejection (20 months)	Normal function (35 months)
SPK	CM	7/10/95	Splenic artery anastomotic pseudoaneurysm, abscess (22 days)	Chronic rejection (14.2 months)
SPK	TM	8/19/95	Necrotizing pancreatitis (1 day)	Death with graft function (24.6 months)
SPK	KS	10/21/95	Thrombosis (1 day)	Normal function (30 months)
SPK	JO	2/16/96	Normal islet function (26 months)	Chronic rejection (17.3 months)
PTA	DY	7/27/95	Rejection (2.5 months)	NA ^c
PTA	DB	9/17/95	Rejection (8.8 months)	NA

^aLigated inferior pancreaticoduodenal artery.

^bImmunosuppression stopped at 14 days.

^cNA, not applicable.

TABLE 3Graft function and metabolic parameters in pancreas-kidney patients receiving TAC^a

Time after transplant (mo)	SCr (mg/dl)	Fasting glucose (mg/dl)	TAC trough level (ng/ml)	TAC dose (mg/day)
1	1.8 ± 1.5	90.8 ± 15.0	15.4 ± 6.1	19.5 ± 7.7
3	1.4 ± 0.5	96.7 ± 20.0	12.8 ± 4.9	13.0 ± 5.9
6	1.4 ± 0.6	89.8 ± 14.8	10.1 ± 3.1	9.5 ± 3.8
12	1.4 ± 0.6	93.9 ± 20.4	10.0 ± 2.9	7.4 ± 2.6
24	1.4 ± 0.8	93.7 ± 18.1	8.4 ± 2.7	6.3 ± 2.1
At follow-up ^b	1.5 ± 0.9	92.0 ± 20.7	8.0 ± 2.0	6.2 ± 1.8
<i>P</i> (ANOVA) ^c	0.035	0.49	<0.001	<0.001

^aSPK patients with functioning grafts.^bMean follow-up: 32.5 ± 6.3 mo.^cAnalysis of variance with repeated measures.